DFDA

NECT (Nifurtimox-Eflornithine Combination Therapy)

Treatment for African Trypanosomiasis

Typical Dosage: Eflornithine 400 mg/kg IV q6h for 7 days; Nifurtimox 15 mg/kg/day orally divided in 3 doses for 10 days

Effectiveness
96%
Safety Score
55%
Clinical Trials
2
Participants
2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Eflornithine 400 mg/kg IV q6h for 7 days; Nifurtimox 15 mg/kg/day orally divided in 3 doses for 10 days
Time to Effect
Within 2-4 weeks post-treatment
Treatment Duration
10 days (Eflornithine IV for 7 days, Nifurtimox oral for 10 days)
Evidence Quality
HIGH
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$1,200
Side Effect Mgmt:$303
Total Annual:$1,803
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
QALYs Gained
4
Outcome-Based Costs
Cost per Responder
$1,878
Cost per Remission
$1,960
NECT (Nifurtimox-Eflornithine Combination Therapy) Outcomes

for African Trypanosomiasis

Efficacy Outcomes
Overall Effectiveness
+96%
Response Rate
+96%
Remission Rate
+92%
Common Side Effects
Diarrhea
+60%
Anemia
+40%
Leukopenia
+30%
Vomiting
+25%
Seizures
+3%

Sources:

dndi.org
nih.gov
dndi.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
2 completed trials for NECT (Nifurtimox-Eflornithine Combination Therapy) in African Trypanosomiasis

Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase

NCT00906880COMPLETEDPHASE4
View Study
630 participants
INTERVENTIONAL
Bandundu, Republic of the Congo +5 more
Started: Apr 1, 2009

Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2

NCT01685827COMPLETEDPHASE2, PHASE3
View Study
394 participants
INTERVENTIONAL
Batangafo, Central African Republic +9 more
Started: Oct 1, 2012